Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention.
Marston NA, Pirruccello JP, Melloni GEM, Koyama S, Kamanu FK, Weng LC, Roselli C, Kamatani Y, Komuro I, Aragam KG, Butterworth AS, Ito K, Lubitz SA, Ellinor PT, Sabatine MS, Ruff CT. Marston NA, et al. Among authors: sabatine ms. JAMA Cardiol. 2023 Feb 1;8(2):130-137. doi: 10.1001/jamacardio.2022.4466. JAMA Cardiol. 2023. PMID: 36576811 Free PMC article.
Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a million participants.
Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, Weeks EM, Wang M, Hindy G, Zhou W, Grace C, Roselli C, Marston NA, Kamanu FK, Surakka I, Venegas LM, Sherliker P, Koyama S, Ishigaki K, Åsvold BO, Brown MR, Brumpton B, de Vries PS, Giannakopoulou O, Giardoglou P, Gudbjartsson DF, Güldener U, Haider SMI, Helgadottir A, Ibrahim M, Kastrati A, Kessler T, Kyriakou T, Konopka T, Li L, Ma L, Meitinger T, Mucha S, Munz M, Murgia F, Nielsen JB, Nöthen MM, Pang S, Reinberger T, Schnitzler G, Smedley D, Thorleifsson G, von Scheidt M, Ulirsch JC; Biobank Japan; EPIC-CVD; Arnar DO, Burtt NP, Costanzo MC, Flannick J, Ito K, Jang DK, Kamatani Y, Khera AV, Komuro I, Kullo IJ, Lotta LA, Nelson CP, Roberts R, Thorgeirsson G, Thorsteinsdottir U, Webb TR, Baras A, Björkegren JLM, Boerwinkle E, Dedoussis G, Holm H, Hveem K, Melander O, Morrison AC, Orho-Melander M, Rallidis LS, Ruusalepp A, Sabatine MS, Stefansson K, Zalloua P, Ellinor PT, Farrall M, Danesh J, Ruff CT, Finucane HK, Hopewell JC, Clarke R, Gupta RM, Erdmann J, Samani NJ, Schunkert H, Watkins H, Willer CJ, Deloukas P, Kathiresan S, Butterworth AS; CARDIoGRAMplusC4D Consortium. Aragam KG, et al. Among authors: sabatine ms. Nat Genet. 2022 Dec;54(12):1803-1815. doi: 10.1038/s41588-022-01233-6. Epub 2022 Dec 6. Nat Genet. 2022. PMID: 36474045 Free PMC article.
Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
Kondo T, Wang X, Yang M, Jhund PS, Claggett BL, Vaduganathan M, Hernandez AF, Lam CSP, Inzucchi SE, Martinez FA, de Boer RA, Kosiborod MN, Desai AS, Køber L, Ponikowski P, Sabatine MS, Langkilde AM, Petersson M, Zaozerska N, Bachus E, Solomon SD, McMurray JJV. Kondo T, et al. Among authors: sabatine ms. J Am Coll Cardiol. 2023 Sep 5;82(10):1014-1026. doi: 10.1016/j.jacc.2023.05.056. Epub 2023 Aug 21. J Am Coll Cardiol. 2023. PMID: 37610398 Free article.
A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).
McMurray JJV, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon SD; DAPA-HF Committees and Investigators. McMurray JJV, et al. Among authors: sabatine ms. Eur J Heart Fail. 2019 May;21(5):665-675. doi: 10.1002/ejhf.1432. Epub 2019 Mar 21. Eur J Heart Fail. 2019. PMID: 30895697 Free PMC article.
Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
Pollack R, Raz I, Wiviott SD, Goodrich EL, Murphy SA, Yanuv I, Rozenberg A, Mosenzon O, Langkilde AM, Gause-Nilsson IAM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Cahn A. Pollack R, et al. Among authors: sabatine ms. Diabetes Care. 2023 Jan 1;46(1):156-164. doi: 10.2337/dc22-1318. Diabetes Care. 2023. PMID: 36399721 Clinical Trial.
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
O'Donoghue ML, Rosenson RS, Gencer B, López JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. O'Donoghue ML, et al. Among authors: sabatine ms. N Engl J Med. 2022 Nov 17;387(20):1855-1864. doi: 10.1056/NEJMoa2211023. Epub 2022 Nov 6. N Engl J Med. 2022. PMID: 36342163 Free article. Clinical Trial.
Encased in Peril.
Kaur G, Sabatine MS, Schaefer IM, Sun YP, Loscalzo J. Kaur G, et al. Among authors: sabatine ms. N Engl J Med. 2023 Nov 2;389(18):1709-1716. doi: 10.1056/NEJMcps2306031. N Engl J Med. 2023. PMID: 37913509 No abstract available.
Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.
Butt JH, Docherty KF, Claggett BL, Desai AS, Fang JC, Petersson M, Langkilde AM, de Boer RA, Cabrera Honorio JW, Hernandez AF, Inzucchi SE, Kosiborod MN, Køber L, Lam CSP, Martinez FA, Ponikowski P, Sabatine MS, Vardeny O, O'Meara E, Saraiva JFK, Shah SJ, Vaduganathan M, Jhund PS, Solomon SD, McMurray JJV. Butt JH, et al. Among authors: sabatine ms. JACC Heart Fail. 2023 Apr;11(4):375-388. doi: 10.1016/j.jchf.2022.11.014. Epub 2023 Feb 1. JACC Heart Fail. 2023. PMID: 36881399 Free article. Clinical Trial.
Dapagliflozin and Physical and Social Activity Limitations in Heart Failure With Reduced Ejection Fraction.
Butt JH, Docherty KF, Kosiborod MN, Inzucchi SE, Køber L, Langkilde AM, Martinez FA, Bengtsson O, Ponikowski P, Sabatine MS, Sjöstrand M, Solomon S, Jhund PS, McMurray JJV. Butt JH, et al. Among authors: sabatine ms. JACC Heart Fail. 2023 Oct;11(10):1411-1423. doi: 10.1016/j.jchf.2023.04.016. Epub 2023 Jun 14. JACC Heart Fail. 2023. PMID: 37318419 Free article.
Influence of body weight and body mass index on the chronic pharmacokinetic and pharmacodynamic responses to clinically available doses of ticagrelor in patients with chronic coronary syndromes.
Parker WAE, Angiolillo DJ, Rollini F, Franchi F, Bonaca MP, Bhatt DL, Steg PG, Orme RC, Thomas MR, Judge HM, Sabatine MS, Storey RF. Parker WAE, et al. Among authors: sabatine ms. Vascul Pharmacol. 2023 Apr;149:107145. doi: 10.1016/j.vph.2023.107145. Epub 2023 Jan 28. Vascul Pharmacol. 2023. PMID: 36720377
524 results